January 2012
Victims continue to file Actos lawsuits against Takeda Pharmaceuticals
- Thu, 01/26/2012 - 9:22am
- Comments
Actos (pioglitazone) is a medication used to regulate insulin in patients diagnosed with type II diabetes.
FDA advisory committee ordered to conduct new Yaz and Yasmin meeting
- Wed, 01/18/2012 - 1:23pm
- Comments
On December 8, 2011, the FDA advisory panel met to discuss the benefits and risks of birth contraceptives Yaz® and Ya
European Commission advocates Actos as valid treatment
- Wed, 01/18/2012 - 1:15pm
- Comments
Despite the concerns associated with the linkage between Actos and bladder cancer, the European Commission advocates that Actos is still a
Documents reveal three FDA advisory panel members previously worked for Bayer
- Wed, 01/18/2012 - 1:12pm
- Comments
The FDA Advisory committee, which voted against a Yaz® and Yasmin® recall during December, is being questioned ab
Judge prolongs Yaz case
- Thu, 01/05/2012 - 4:30pm
- Comments
Bayer, the manufacturer of Yaz and Yasmin®, now faces over 10,000 lawsuits brought by women who allege
Increased blood clot risk associated with newer birth controls
- Thu, 01/05/2012 - 1:29pm
- Comments
Actos litigation centralized in Louisiana
- Thu, 01/05/2012 - 1:25pm
- Comments
Actos (pioglitazone) was first introduced in July of 1999 and was designed to aid the body’s sensitivity to insulin in patients that have been diagnosed with type II diabetes.